Clinical trial NCT00371124 - References

Myopia — Safety and Efficacy Study of 0.5%, 0.1% & 0.01% Atropine Treatment to Both Eyes In Treatment of Myopia In Children

Citation(s)

•   Bedrossian RH
  The effect of atropine on myopia. Ophthalmology. 1979 May;86(5):713-9.
•   Chua WH, Balakrishnan V, Chan YH, ATOM Study Group
  Analysis of the safety data from the atropine in the treatment of myopia (ATOM) study. Invest Ophthalmol Vis Sci 2002;43:E-Abstract 3329.
•   Chua WH, Balakrishnan V, Tan D, Chan YH, ATOM Study Group
  Efficacy results from the atropine in the treatment of myopia (ATOM) study. Invest Ophthalmol Vis Sci 2003;44:E-Abstract 3119.
•   Lee JJ, Fang PC, Yang IH, Chen CH, Lin PW, Lin SA, Kuo HK, Wu PC
  Prevention of myopia progression with 0.05% atropine solution. J Ocul Pharmacol Ther. 2006 Feb;22(1):41-6.
•   McBrien NA, Moghaddam HO, Reeder AP
  Atropine reduces experimental myopia and eye enlargement via a nonaccommodative mechanism. Invest Ophthalmol Vis Sci. 1993 Jan;34(1):205-15.
•   Shih YF, Chen CH, Chou AC, Ho TC, Lin LL, Hung PT
  Effects of different concentrations of atropine on controlling myopia in myopic children. J Ocul Pharmacol Ther. 1999 Feb;15(1):85-90.
•   Shih YF, Hsiao CK, Chen CJ, Chang CW, Hung PT, Lin LL
  An intervention trial on efficacy of atropine and multi-focal glasses in controlling myopic progression. Acta Ophthalmol Scand. 2001 Jun;79(3):233-6.

A Randomised, Double-Masked Study to Compare The Safety and Efficacy of Bilateral 0.5%, 0.1% & 0.01% Atropine Treatment In Controlling Progression of Myopia In Children

Details for clinical trial NCT00371124